We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

Nimbus Announces Change to Business Board

Read time: Less than a minute

Nimbus Biotechnology has reported a change to the company’s Supervisory Board. Professor Axel Kleemann, formerly executive board member of Asta Medica AG has been appointed as a new member and chairman of the Supervisory Board.

Professor Thomas Bayerl, Dr. Rainer Strohmenger (Wellington Partners Venture Capital GmbH, Germany), Jack Griffin and Mario Ober (CFH, Germany) continue to be board members.

Nimbus Biotechnology thanks Werner Zollner (Seed GmbH, Germany) for his former work and support in this position.

Wolfgang Lerch, CEO of Nimbus Biotechnology, stated, "The appointment of Professor Axel Kleemann is a very special opportunity for Nimbus Biotechnology."

"With his expertise we will strengthen our mission to support our customers with cutting-edge tools."

"We will come closer to developing modern tools for all stages of drug discovery. All employees of the company wish him success for his work."